Merck & Co., Inc.
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Invanz (ertapenem, legacy) by Year
Invanz (ertapenem, legacy) — Worldwide reported growth YoY (%) (%)
Merck Invanz (ertapenem, legacy): -4.0% in FY2021, up 16.0 pts from a year earlier. No newer figure appears in the documents we track.
Where the FY2021 figure comes from
“|| Invanz | 202 | 211 | -4 | (5 | ) | 9 | -157 | 207 | 202 | 3”
Source: Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗
Reported in Form 8-K Table 3 / 3a / 3b Product Sales.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Invanz (ertapenem, legacy) — Worldwide reported growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2021 | Dec 31, 2021 | -4.0% | +16.0 pts | Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗ |
| FY2020 | Dec 31, 2020 | -20.0% | +27.0 pts | Form 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗ |
| FY2019 | Dec 31, 2019 | -47.0% | -29.0 pts | Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗ |
| FY2018 | Dec 31, 2018 | -18.0% | -25.0 pts | Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗ |
| FY2017 | Dec 31, 2017 | 7.0% | – | Form 8-K (a18-5152_1ex99d1.htm, filed 2018-02-02) ↗ |
Cite this data
StockData. (2026). Merck Invanz (ertapenem, legacy) (%), annual FY2017–FY2021 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-invanz-ww-nom-yoy
See every metric in the Merck KPI table. Data updated Oct 26, 2026.